– Anjarium’s versatile platform combines proprietary genetic vectors, targeted non-viral delivery technologies and efficient manufacturing solutions to unleash the full potential of gene therapy
– The product will be used for business growth, to expand its platform and advance its pipeline
– Series A co-led by Abingworth and Gimv, alongside Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company)
ZURICH, September 16, 2021 / PRNewswire / – Anjarium Biosciences AG (âAnjariumâ), a biotechnology company focused on creating and delivering a new class of non-viral gene therapies, today announced the closing of a CHF55.5M ($ 61 million) Series A financing. The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
Anjarium’s innovative approach draws on cutting-edge science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to rationally design and produce gene therapies targeted at tissues, optimized to improve patient outcomes in a range of serious genetic diseases.
The company’s unique platform combines proprietary DNA-based genetic vectors, delivery modalities for natural and synthetic nanoparticles – including its new Hybridosome â¢ technology – and scalable and cost-effective manufacturing solutions.
Through this approach, Anjarium has the potential to provide more predictable, sustainable and inclusive ways to fight genetic diseases throughout a patient’s life. In addition, this new class of gene therapy offers the possibility of filling the main gaps in the current development of viral gene therapy by creating drugs with reduced immunogenicity, increased payload capacity, improved targeted delivery and individualized multiple dosing. .
Proceeds from the Series A funding will allow Anjarium to expand its team, advance its groundbreaking platform, and advance several therapeutic pipeline programs into clinical development.
“As the limitations of conventional gene therapies based on viral vectors for delivering optimal patient outcomes become increasingly evident, a completely non-viral approach represents an exciting new therapeutic opportunity.” said JoÃ«l de Beer, Founder and CSO of Anjarium Biosciences. âBacked by this syndicate of leading investors, the Anjarium team looks forward to continuing to create and deliver patient solutions beyond what current gene therapy platforms can handle, including attacking more diseases, in a more precise and personalized way.
Bali Muralidhar, Managing Partner at Abingworth, said: âAdvanced therapies such as non-viral gene therapies have the potential to provide lifelong benefits to patients with genetic diseases. Anjarium has an exciting and versatile technology that offers a wide opportunity to improve and extend the scope of gene therapy. We look forward to supporting the team in developing their technology and translating their innovative science into life-changing products. ”
Bram vanparys, partner at Gimv, added: âWe are very happy to support Anjarium, as its groundbreaking science, platform and manufacturing setup have tremendous potential to change the way we approach gene therapy today – with the ability to deliver products with much better results and durability. “
In conjunction with Anjarium Series A funding, Dr Bali Muralidhar from Abingworth, Dr. Bram vanparys by Gimv and Dr. Dina chaya Omega Funds will join the board of directors of the company.
About Anjarium Biosciences
Anjarium is focused on creating a new class of non-viral gene therapies to provide more predictable, sustainable, and inclusive ways to fight genetic diseases throughout a patient’s life. The Company’s versatile platform aims to leverage cutting-edge science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current gene therapies based on viral vectors.
Anjarium’s investors include major international and strategic investors Abingworth, Gimv, Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). www.anjarium.com
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into new drugs by providing capital and expertise to high-caliber management teams who build world-class businesses. Since 1973, Abingworth has invested in more than 175 life science companies, leading to 45 million& As and 71 IPOs. Our therapy-focused investments fall into three categories: initiation and early stage, developmental stage and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals in offices in London, Menlo Park (California), and Boston. www.abingworth.com
Gimv is a European investment company, listed on Euronext Brussels, with nearly 40 years of experience in private equity and venture capital. The company currently has a portfolio of 1.1 billion euros investments in around fifty portfolio companies, with cumulative turnover of 2.75 billion euros and 14,000 employees. As a recognized market leader on selected investment platforms, Gimv identifies innovative entrepreneurial companies with high growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. More information about Gimv can be found at www.gimv.com
About Omega Funds
Founded in 2004, Omega Funds is a leading international investment firm that creates and invests in life science companies that target the most urgent medical needs of our world. Omega is focused on identifying and supporting businesses through inflection points of value across the innovation arc, from company formation to clinical stages and commercial adoption. The Omega Fund portfolio companies have brought to market 39 products in multiple therapeutic areas, including oncology, rare diseases, precision medicine and others. Please visit www.omegafunds.com for more information.
Mark Swallow, George Underwood, Eleanor Perkin
View original content: https://www.prnewswire.com/news-releases/anjarium-biosciences-raises-chf-55-5m-61m-series-a-financing-to-develop-next-generation-non-viral – gene-therapies-301377917.html
SOURCE Anjarium Biosciences